Laura E. Niklason - May 31, 2024 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
May 31, 2024
Transactions value $
-$7,832,200
Form type
4
Date filed
6/4/2024, 06:57 PM
Previous filing
Dec 12, 2023
Next filing
Jun 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Sale -$5.57M -717K -11.57% $7.78 5.47M May 31, 2024 By Ayabudge LLC F1, F2
transaction HUMA Common Stock Sale -$832K -93.2K -1.7% $8.93 5.38M May 31, 2024 By Ayabudge LLC F1, F3, F4
transaction HUMA Common Stock Sale -$1.41M -190K -3.53% $7.42 5.19M Jun 3, 2024 By Ayabudge LLC F1, F5
transaction HUMA Common Stock Sale -$13.5K -1.85K -0.04% $7.28 5.19M Jun 4, 2024 By Ayabudge LLC F1, F6
holding HUMA Common Stock 238K May 31, 2024 Direct
holding HUMA Common Stock 510K May 31, 2024 By spouse
holding HUMA Common Stock 1.15M May 31, 2024 By The Niklason Living Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.
F2 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.405 to $8.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Dr. Niklason of 2,050 shares of the Issuer's common stock on June 3, 2024, at a price per share of $7.37. The Reporting Person has paid the Issuer $4,007.76, representing the full amount of profit realized in connection with this sale.
F4 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.41 to $9.345. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.625. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.265 to $7.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.